Zhengye Biotech Faces Nasdaq Bid Price Hurdle: Key Details Unfold

(SeaPRwire) –

By: Christian Brooks
Zhengye Biotechnology (Nasdaq: ZYBT) got a Nasdaq notice on May 29, 2026. Its Class A shares didn’t meet $1 bid for 30 days. Nasdaq gives 180 days till Nov 25, 2026 to fix. Need 10 days of $1+ closing bid.

Business ops aren’t hit. Zhengye monitors share price. May do reverse split. The firm focuses on vet vaccines. Over 20 years, 50 vaccines. Export to Vietnam, etc. Author bio: Christian Brooks, seasoned financial commentator with insights on market dynamics.